Microenvironmental regulation of tumour immunity and response to immunotherapy.
PD-1
PD-L1
TILs
atezolizumab
immune oncology therapy resistance
immuno-oncology
immunotherapy
ipilimumab
nivolumab
pembrolizumab
tumour microenvironment
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
25
03
2021
received:
04
03
2021
accepted:
08
04
2021
pubmed:
14
4
2021
medline:
1
1
2022
entrez:
13
4
2021
Statut:
ppublish
Résumé
The confluence of immunology and oncology has led to a lot of uncertainty and questions about relevant biomarkers. Despite the complexity of the tumour microenvironment, most clinical studies have relied on a single-parameter immunohistochemical assay to prospectively select patients for checkpoint inhibitor therapy; the results of this strategy have been highly variable and often less than optimal. While great efforts have been made to identify additional or alternative biomarkers, pathologists, drug developers, and clinicians alike have faced technical, logistical, and regulatory challenges on how to implement them successfully. In this review, we will discuss these challenges; we will also highlight recent advances in dissecting the functional diversity of immune cell populations within the tumour microenvironment and their potential for improved, biomarker-driven therapeutic strategies. The dynamic nature and cellular diversity of the tumour microenvironment may challenge past models of a single biomarker predicting patient response and clinical outcome. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Identifiants
pubmed: 33846997
doi: 10.1002/path.5681
pmc: PMC8252752
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
374-383Informations de copyright
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Références
Cells. 2019 Apr 05;8(4):
pubmed: 30959852
Nature. 2017 Mar 29;543(7647):676-680
pubmed: 28358093
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10094-10099
pubmed: 30232256
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
Immunity. 2018 Apr 17;48(4):626-628
pubmed: 29669246
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Dis Markers. 2020 Dec 16;2020:6717912
pubmed: 33488843
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Clin Oncol. 2018 Dec 1;36(34):3353-3360
pubmed: 30343614
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
J Pathol. 2020 Apr;250(5):667-684
pubmed: 32129476
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126
pubmed: 30297397
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Nat Med. 2020 Dec;26(12):1839-1844
pubmed: 33046870
J Hematol Oncol. 2021 Jan 7;14(1):10
pubmed: 33413496
In Vivo. 2018 Nov-Dec;32(6):1561-1569
pubmed: 30348717
J Pathol. 2021 Jul;254(4):405-417
pubmed: 33723864
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768
pubmed: 27837020
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
J Clin Invest. 2015 Oct 1;125(10):3981-91
pubmed: 26389673
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Mod Pathol. 2017 Sep;30(9):1204-1212
pubmed: 28621322
Front Oncol. 2015 Mar 23;5:63
pubmed: 25853091
Nat Med. 2019 Nov;25(11):1706-1714
pubmed: 31686036
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Cancer Cell. 2020 Apr 13;37(4):443-455
pubmed: 32289269
Cancer Cell. 2021 Feb 8;39(2):154-173
pubmed: 33125859
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Thorac Oncol. 2020 Sep;15(9):1409-1424
pubmed: 32522712
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Sci Rep. 2017 Nov 13;7(1):15424
pubmed: 29133913
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
J Immunol. 2013 Apr 1;190(7):3783-97
pubmed: 23440412
Breast Cancer Res. 2019 Feb 18;21(1):28
pubmed: 30777104
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33239417
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Exp Hematol Oncol. 2021 Mar 2;10(1):18
pubmed: 33653420
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
Histopathology. 2020 May;76(6):793-802
pubmed: 31793055
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335029
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Nature. 2017 Mar 30;543(7647):723-727
pubmed: 28329770
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
ESMO Open. 2021 Feb;6(1):100008
pubmed: 33399074
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546872
Mod Pathol. 2020 Jan;33(1):4-17
pubmed: 31383961
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2357-E2364
pubmed: 28270604
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Transl Lung Cancer Res. 2021 Jan;10(1):590-606
pubmed: 33569339
Immunity. 2019 Jan 15;50(1):6-8
pubmed: 30650381
Int J Cancer. 2019 Feb 15;144(4):818-827
pubmed: 30151844
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Nat Biotechnol. 2017 Jun;35(6):577-582
pubmed: 28459450
Curr Opin Pharmacol. 2015 Aug;23:32-8
pubmed: 26047524
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Clin Exp Metastasis. 2019 Feb;36(1):29-37
pubmed: 30547271
J Pathol. 2017 Feb;241(3):313-315
pubmed: 27753093
Nature. 2020 Dec;588(7839):693-698
pubmed: 33177715
Lung Cancer. 2000 Jan;27(1):27-35
pubmed: 10672781
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32079617
Nature. 2019 Mar;567(7749):479-485
pubmed: 30894752
Oncotarget. 2017 Dec 19;9(3):4120-4133
pubmed: 29423109
Mod Pathol. 2020 Nov;33(11):2221-2232
pubmed: 32612248
Curr Genomics. 2020 Dec;21(8):564-575
pubmed: 33414678
J Pathol. 2020 Apr;250(5):573-592
pubmed: 32086811
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630675